Key Facts Surrounding This News Item
- TBIO had returned 0.00% year-to-date leading up to today’s news, versus a +1.79% return from the benchmark S&P 500 during the same period.
More Info About Translate Bio, Inc. (TBIO)
Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts. View our full TBIO ticker page with ratings, news, and more.